论文部分内容阅读
给 6名健康青年男性受试者皮下注射重组人红细胞生成素 (rhEPO) ,剂量为 3 0IU/kg体重 ,每周 3次 ,注射持续 4周。同时给 4名对照受试者注射安慰剂。采用酶联免疫吸附法 (ELISA)进行指标测定。结果表明 :注射rhEPO能提高血清EPO浓度和转铁蛋白可溶性受体 (TfR)浓度 ;在停药后 1个星期左右的时间内 ,TfR浓度仍保持在较高的水平 ;而血浆总纤维蛋白和纤维蛋白原降解产物 (TDP)含量未发现规律性的变化。结果提示 :血清EPO和TfR浓度有可能作为rhEPO滥用检测的指标。
Six healthy young male subjects were subcutaneously injected with recombinant human erythropoietin (rhEPO) at a dose of 30 IU / kg body weight three times a week for 4 weeks. Four control subjects were also given a placebo. Enzyme-linked immunosorbent assay (ELISA) was used to determine the index. The results showed that: the injection of rhEPO can increase serum EPO concentration and transferrin-soluble receptor (TfR) concentration; in about a week after stopping the TfR concentration remained at a high level; while plasma total fibrin and Fibrinogen degradation products (TDP) content found no regular changes. The results suggest that serum EPO and TfR concentrations may be used as indicators of rhEPO abuse detection.